Study S000146

Effects Of Exenatide (Byetta®) On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Non-Alcoholic Fatty Liver Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00529204
Study type: INTERVENTIONAL
Phase: PHASE2
Masking: NONE
Status: TERMINATED
Enrollment: 1
Start: 2007-10
Primary completion: 2009-07
Lead sponsor: University of California, Davis
Conditions: Diabetes Complications; Fatty Liver
Interventions: DRUG:exenatide
Results posted: TRUE
Secondary identifiers: OTHER:H80-MC-X006

Registered primary outcomes

Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy [24 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026490	Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Buse JB, Clinical therapeutics	2007	Randomized trial	PMID 17379054 DOI	registry reference BACKGROUND:17379054